Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CEA CAR-T in pancreatic cancer liver metastases
NCT04037241Phase 3Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 3 trial of CAR2 anti-CEA CAR-T cells in pancreatic adenocarcinoma (PDAC), sponsored by Sorrento Therapeutics. Planned start Nov 2021; status: withdrawn.
02
Drugs
CAR2 anti-CEA CAR-T cells
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04037241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037241.